Business Context and Reporting Period
This Form 8-K reports on the 2023 Annual Meeting of Stockholders held by Reneo Pharmaceuticals, Inc. on June 6, 2023. The record date for the meeting was April 10, 2023, with 25,107,430 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals:
- Proposal 1: Election of Directors - Three Class III directors were elected to serve until the 2026 Annual Meeting.
- Edward T. Mathers: 15,749,259 For; 815,951 Abstain; 3,763,543 Broker Non-Votes.
- Bali Muralidhar, M.D., Ph.D.: 15,423,901 For; 1,141,309 Abstain; 3,763,543 Broker Non-Votes.
- Stacey D. Seltzer: 15,937,901 For; 627,309 Abstain; 3,763,543 Broker Non-Votes.
- Proposal 2: Ratification of Independent Auditor - Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Results: 20,316,020 For; 12,633 Against; 100 Abstain; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the tenure of the newly elected Class III directors (Edward T. Mathers, Bali Muralidhar, and Stacey D. Seltzer) through the 2026 Annual Meeting.
- Confirm the engagement of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2023.
- Note the significant number of broker non-votes (3,763,543) on the director election proposals, which may indicate shares held in street name where brokers lacked discretionary voting power.